SGMO Stock News & Analysis | Latest Updates

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

(NASDAQ:SGMO) SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT INTERNATIONAL CONGRESS OF INBORN ERRORS OF METABOLISM 2025

September 4, 2025Clinical Trials

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

SGMO

May 14, 2025

Sangamo Therapeutics Q1 EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

SGMO

May 12, 2025

Sangamo Therapeutics Prices $23M Underwritten Offering Of 12.235M Shares Of Common Stock And Pre-Funded Warrants At $0.50 And $0.49 Respectively, Including Accompanying Warrants Exercisable At $0.75

SGMO

May 12, 2025

Sangamo Therapeutics Q1 GAAP EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

SGMO

May 12, 2025

Sangamo Therapeutics Announces Postponement Of First Quarter 2025 Conference Call To 6:30PM Eastern May12 ,2025

SGMO

May 12, 2025

Sangamo Therapeutics Announces Derisking Milestones For Pathway To Anticipated BLA Submission For ST-920 In Fabry Disease

SGMO

May 6, 2025

Sangamo Therapeutics To Present At 28th Annual Meeting of the American Society of Gene & Cell Therapy May 13-17

SGMO

April 28, 2025

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

SGMO

April 7, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know

SGMO

March 18, 2025

RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target

SGMO

March 18, 2025

Sangamo Therapeutics Expects FY25 Operating Expenses On A Non-GAAP Basis Are To Be Roughly In Line With 2024

SGMO

March 17, 2025

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

SGMO

March 17, 2025

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

SGMO

December 20, 2024

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

SGMO

December 19, 2024

Sangamo Licenses STAC-BBB Technology To Astellas To Drive Genomic Medicine For Neurological Diseases

SGMO

December 19, 2024

Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy

SGMO

November 19, 2024

Sangamo Therapeutics Gains FDA Clearance For IND Application Of ST-503 To Treat Idiopathic Small Fiber Neuropathy, Aiming To Address Chronic Neuropathic Pain With Phase 1/2 Study Enrollment Set For Mid-2025

SGMO

November 19, 2024

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

SGMO

November 14, 2024

HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Raises Price Target to $10

SGMO

November 5, 2024

Sangamo Therapeutics's Earnings: A Preview

SGMO

Sangamo Therapeutics (NASDAQ:SGMO) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Sangamo Therapeutics will report an earnings per share (EPS) of $-0.31.

May 4, 2022

Sangamo Therapeutics To Present Data From Its Next-Generation Technologies At 2022 Annual Meeting Of The American Society Of Gene & Cell Therapy

SGMO

May 2, 2022

SGMO News

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Sangamo Therapeutics Q1 EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

Sangamo Therapeutics Prices $23M Underwritten Offering Of 12.235M Shares Of Common Stock And Pre-Funded Warrants At $0.50 And $0.49 Respectively, Including Accompanying Warrants Exercisable At $0.75

Sangamo Therapeutics Q1 GAAP EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

Sangamo Therapeutics Announces Postponement Of First Quarter 2025 Conference Call To 6:30PM Eastern May12 ,2025

Sangamo Therapeutics Announces Derisking Milestones For Pathway To Anticipated BLA Submission For ST-920 In Fabry Disease

Sangamo Therapeutics To Present At 28th Annual Meeting of the American Society of Gene & Cell Therapy May 13-17

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

8 Analysts Assess Sangamo Therapeutics: What You Need To Know

RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target

Sangamo Therapeutics Expects FY25 Operating Expenses On A Non-GAAP Basis Are To Be Roughly In Line With 2024

Sangamo Therapeutics Q4 2024 GAAP EPS $(0.11) Misses $(0.08) Estimate, Sales $7.551 Miss $13.617M Estimate

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

Sangamo Licenses STAC-BBB Technology To Astellas To Drive Genomic Medicine For Neurological Diseases

Sangamo Therapeutics Gets FDA Clearance Of IND Application For ST-503 For Treatment Of Idiopathic Small Fiber Neuropathy

Sangamo Therapeutics Gains FDA Clearance For IND Application Of ST-503 To Treat Idiopathic Small Fiber Neuropathy, Aiming To Address Chronic Neuropathic Pain With Phase 1/2 Study Enrollment Set For Mid-2025

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Raises Price Target to $10

Sangamo Therapeutics's Earnings: A Preview

Sangamo Therapeutics To Present Data From Its Next-Generation Technologies At 2022 Annual Meeting Of The American Society Of Gene & Cell Therapy